Immune tolerance deletes or suppresses autoreactive lymphocytes and is established at
multiple levels during the development, activation and effector phases of T and B cells …

Context Concomitant obesity is common amongst patients with type 1 diabetes mellitus
(T1DM), yet adjunctive therapy options are scarce. Objective We assess the efficacy and …

Hyperglucagonemia contributes to hyperglycemia in patients with type 1 diabetes (T1D);
however, novel therapeutics that block glucagon action could improve glycemic control. This …

Objective This study evaluated whether adding sodium‐glucose cotransporter‐2 inhibitors
(SGLT2i) and/or glucagon‐like peptide‐1 receptor agonists (GLP1‐RA) to insulin reduced …

Incretin-based therapies, in particular glucagon-like peptide-1 (GLP-1) receptor agonists,
have been evaluated in other forms of diabetes, but randomised controlled trials are mainly …

Abstract Background: Type 1 diabetes (T1D) is a chronic autoimmune disease characterized
by progressive destruction of the pancreatic beta cells, leading to a lifelong dependence on …

Background: To assess the efficacy and safety of glucagon-like peptide-1 receptor agonists
(GLP-1 RAs) used as an adjunct to insulin therapy in adults with type 1 diabetes. Methods: A …

Introduction There have been many recent advances in the treatment of type 1 diabetes
(T1D) including in insulin formulations, continuous glucose monitoring (CGM) technology …

Obesity, a chronic low-grade inflammatory disease represented by multifactorial metabolic
dysfunctions, is a significant global health threat for adults and children. The once-held …

(1) Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are a class of
therapeutic agents that mimic the endogenous incretin hormone GLP-1. While this class of …